Cleveland BioLabs, Inc. is a biotechnology company based in Buffalo, NY, specializing in the development of innovative drugs and therapies. With a focus on biodefense and oncology, the company's pipeline includes promising candidates such as ENTOLIMOD CBLB502, a potential treatment for radiation exposure, and CBLB612, a synthetic lipopeptide that stimulates white blood cell regeneration and shows potential in enhancing anti-tumor efficacy.
Through their cutting-edge technology and scientific research, Cleveland BioLabs aims to address critical medical needs and improve patient outcomes. With a strong management team and strategic alliances, the company is dedicated to advancing their pipeline and exploring licensing opportunities to bring their innovative therapies to market.
Generated from the website